Skip to content
OpenCapital
Get started
Indivior Pharmaceuticals, Inc. logo

Indivior Pharmaceuticals, Inc. (INDV) Q1 2026 Earnings

INDV·Reported April 30, 2026·Before market open

Indivior Pharmaceuticals, Inc. reported Q1 2026 revenue of $317.0M (+19.2% YoY), beat analyst consensus of $272.8M by $44.2M. Diluted EPS came in at $0.96 (+134.1% YoY), beat the $0.64 consensus by $0.32.

Revenue
$317.0Mbeat by $44.2M
Consensus: $272.8M
Diluted EPS
$0.96beat by $0.32
Consensus: $0.64
SEC

SEC Filings

Earnings release8-K · 0001193125-26-193925
Quarterly report10-Q · 0001628280-26-028850

Financial Snapshot

Trailing eight quarters through Q1 2026

View all metrics

Q1 2026 Earnings FAQ

Common questions about Indivior Pharmaceuticals, Inc. 's Q1 2026 earnings report.

Indivior Pharmaceuticals, Inc. (INDV) reported Q1 2026 earnings on April 30, 2026 before market open.

Indivior Pharmaceuticals, Inc. reported revenue of $317.0M and diluted EPS of $0.96 for Q1 2026.

Revenue beat the consensus estimate of $272.8M by $44.2M. EPS beat the consensus estimate of $0.64 by $0.32.

Compared to the same quarter a year prior, revenue grew 19.2% from $266.0M a year earlier and diluted EPS grew 134.1% from $0.41.

You can read the 8-K earnings release (0001193125-26-193925) and the 10-Q periodic report (0001628280-26-028850) directly on SEC EDGAR. The filing index links above go to sec.gov.